Print
Health Care

PPD Collaborates With Biopharma Company On Oncology, Immunology Therapies

By Christina Haley O'Neal, posted Aug 28, 2019
Wilmington-based Pharmaceutical Product Development (PPD) recently announced its collaboration with a global clinical-stage biopharmaceutical company to develop oncology and immunology therapeutics.

Harbour BioMed (HBM) has selected PPD as its preferred global contract research partner to conduct clinical studies on its internal research pipelines, according to a news release.

The company is using PPD Biotech services, which, according to its website, finds phase I through IV clinical development solutions for biotech and small to midsize pharmaceutical companies.

The two companies recently completed an Australian ethics committee submission for HBM’s anti-cancer immunotherapy to target solid tumors, stated the release. They reached a milestone ahead of schedule, “on the path to Phase I trials in Australia and the United States,” according to the release.

“Our enthusiasm for the opportunity to support the development of HBM’s innovative assets is equaled by our shared commitment to helping accelerate the delivery of life-changing therapies to patients,” Anshul Thakral, executive vice president and global head of PPD Biotech, said in the release.

PPD Biotech was formed several years ago, and in the past five years, has worked with more than 270 biotech and small pharma clients on more than 650 studies, a PPD spokesperson said in an email Wednesday.

“Harbour BioMed’s selection of PPD Biotech as its preferred partner is further evidence that pairing our unique biotech perspective with our scalable global development services is a powerful combination for our customers," Thakral said. "Collaborating with experts at Harbour BioMed in the early stages of its product development enabled our seasoned medical and operational oncology leaders to offer the right tailored, forward-thinking strategy."

HBM has been developing a “robust pipeline in oncology and immunology” since it was established in 2016, stated the release. The company, which is a clinical-stage biopharma company developing therapeutics in the fields of immuno-oncology and inflammatory diseases, has operations in Cambridge, Massachusetts, The Netherlands and China.

“I’m pleased that our collaborative partnership already has enabled us to achieve the important milestone of our first global [ethics committee] submission, and ahead of our aggressive schedule. We look forward to entering the clinical trial phase of our development programs with PPD as we pursue our global vision and ambition of delivering next-gen therapeutics to fulfill patient needs around the world,” Jingsong Wang, founder, chairman and CEO of HBM, said in the release.
Ico insights

INSIGHTS

SPONSORS' CONTENT
Burrus rob headshot 300x300

Forecasting the Future: Demystifying Two Common Assumptions in Our Economy

Robert Burrus - Cameron School of Business - UNC-Wilmington
Jasonpathfinder3

Life Expectancy on the Rise — are You Prepared?

Jason Wheeler - Pathfinder Wealth Consulting
Alyce 4 april242017

Duties of A Trustee: Choose Wisely

Alyce Phillips - Old North State Trust LLC

Trending News

Boutique Hotel Opening Downtown

Johanna Cano - Sep 13, 2019

In The Current Issue

Low Industrial Space Has Impact

The Wilmington area might be losing out on some employers because of its lack of certain kinds of industrial space....


A Guide To Local Women's Professional Groups

The number of local groups to help women grow professionally and in the community continues to expand....


Officials Study Blue Clay Site's Potential

The county-owned property at 4301 Blue Clay Road has been the center of a contract between to explore future possibilities for the site....

Book On Business

The 2019 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!


Galleries

Videos

August 26, 2019 Power Breakfast: A Healthy Sale?
WILMA's Leadership Accelerator
2019 WilmingtonBiz Expo Keynote Lunch - CEO, nCino, Pierre Naude`